Stock Research: Zoetis

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Zoetis

NYQ:ZTS US98978V1035
70
  • Value
    68
  • Growth
    46
  • Safety
    Safety
    86
  • Combined
    85
  • Sentiment
    29
  • 360° View
    360° View
    70
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Zoetis Inc. is a global animal health company focused on the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products, and services for animals. They operate in the animal health industry, offering products for companion animals (dogs, cats, horses) and livestock (cattle, poultry, swine, fish, sheep). Zoetis markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia, and South America. In the last fiscal year, the company had a market cap of $68,055 million, profits of $6,542 million, revenue of $9,256 million, and 13800 employees.

more

ANALYSIS: With an Obermatt 360° View of 70 (better than 70% compared with alternatives), overall professional sentiment and financial characteristics for the stock Zoetis are above average. The 360° View is based on consolidating four consolidated indicators, with half the metrics below and half above average for Zoetis. The consolidated Value Rank has an attractive rank of 68, which means that the share price of Zoetis is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 68% of alternative stocks in the same industry. The company is also safely financed with a Safety rank of 86. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of 29. Professional investors are more confident in 71% other stocks. The consolidated Growth Rank also has a low rank of 46, which means that the company is below average in terms of growth momentum when looking at financial metrics such as revenue, profit, invested capital growth, and stock returns. 54 of its competitors have better growth. ...read more

more
Index
D.J. US Health Care
D.J. US Pharmaceutical
S&P 500
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 19-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
68 20 17 25
Growth
46 35 71 83
Safety
Safety
86 46 41 34
Sentiment
29 82 98 84
360° View
360° View
70 28 72 66
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
7 78 67 63
Opinions Change
50 13 44 23
Pro Holdings
n/a 76 89 84
Market Pulse
26 95 91 74
Sentiment
29 82 98 84
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
68 20 17 25
Growth
46 35 71 83
Safety Safety
86 46 41 34
Combined
85 9 28 34
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
49 7 7 10
Price vs. Earnings (P/E)
29 34 28 22
Price vs. Book (P/B)
12 1 1 1
Dividend Yield
97 86 84 86
Value
68 20 17 25
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
49 53 62 39
Profit Growth
96 27 49 62
Capital Growth
37 48 36 64
Stock Returns
20 43 81 91
Growth
46 35 71 83
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
16 24 19 23
Refinancing
94 18 27 17
Liquidity
78 91 82 79
Safety Safety
86 46 41 34

Similar Stocks

Discover high‑ranked alternatives to Zoetis and broaden your portfolio horizons.

Aramark

NYQ:ARMK
Country: USA
Industry: Restaurants
Size: X-Large
Full Stock Analysis

Academy Sports and Outdoors

NSQ:ASO
Country: USA
Industry: Specialty Stores
Size: Large
Full Stock Analysis

Stewart Information

NYQ:STC
Country: USA
Industry: Property & Casualty Insurance
Size: Medium
Full Stock Analysis

Phibro Animal Health

NMQ:PAHC
Country: USA
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

This stock is a good value with safe financing, but has low growth and negative sentiment. It is a good option for a cautious value investor looking for stability but who can tolerate low momentum and skeptical professional opinion.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: